This phase II ComboMATCH treatment trial evaluates the effectiveness of palbociclib and binimetinib in treating patients with RAS-mutated cancers. Palbociclib and binimetinib are both in a class of medications called kinase inhibitors. They work by blocking the action of abnormal proteins that signals cancer cells to multiply. This trial may help researchers understand if giving the combination of palbociclib and binimetinib can help improve the amount of time before the cancer grows in patients with patients with low grade serous ovarian cancer who have certain changes in the tumor DNA. This trial may also help researchers understand if giving the combination of palbociclib and binimetinib can help improve outcomes among patients with low grade serous ovarian cancer who have previously received a MEK inhibitor. For patients with other tumors, with the exception of lung cancer, colon cancer, melanoma and low grade serous ovarian cancers, this trial may help researchers understand if giving the combination of palbociclib and binimetinib can improve the clinical outcome of survival without progression in patients who have certain changes in their tumor's DNA.
Exocrine Pancreas Carcinoma, Malignant Solid Neoplasm, Ovarian Low Grade Serous Adenocarcinoma, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
This phase II ComboMATCH treatment trial evaluates the effectiveness of palbociclib and binimetinib in treating patients with RAS-mutated cancers. Palbociclib and binimetinib are both in a class of medications called kinase inhibitors. They work by blocking the action of abnormal proteins that signals cancer cells to multiply. This trial may help researchers understand if giving the combination of palbociclib and binimetinib can help improve the amount of time before the cancer grows in patients with patients with low grade serous ovarian cancer who have certain changes in the tumor DNA. This trial may also help researchers understand if giving the combination of palbociclib and binimetinib can help improve outcomes among patients with low grade serous ovarian cancer who have previously received a MEK inhibitor. For patients with other tumors, with the exception of lung cancer, colon cancer, melanoma and low grade serous ovarian cancers, this trial may help researchers understand if giving the combination of palbociclib and binimetinib can improve the clinical outcome of survival without progression in patients who have certain changes in their tumor's DNA.
Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
-
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States, 35233
University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States, 36688
UCHealth University of Colorado Hospital, Aurora, Colorado, United States, 80045
Poudre Valley Hospital, Fort Collins, Colorado, United States, 80524
Cancer Care and Hematology-Fort Collins, Fort Collins, Colorado, United States, 80528
UCHealth Greeley Hospital, Greeley, Colorado, United States, 80631
Medical Center of the Rockies, Loveland, Colorado, United States, 80538
UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States, 33180
UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States, 33146
UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States, 33442
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
National Cancer Institute (NCI),
Geoffrey I Shapiro, PRINCIPAL_INVESTIGATOR, Alliance for Clinical Trials in Oncology
2026-08-26